In pediatric B-ALL, IKZF1 deletion occurs in 15% of patients and is associated with a higher risk of relapse, thus indicating its importance as a prognostic biomarker.4, 5, 6, 7. Here, IKZF1 is linked to precursor B-cell acute lymphoblastic leukemia.